AcquisitionsJun 24, 2026, 10:43 AM
GSK Commences Tender Offer to Acquire Nuvalent for $124/Share
AI Summary
GSK plc announced that its indirect wholly-owned subsidiary, Harmony Row Acquisition Co., has commenced a tender offer to acquire all outstanding Class A and Class B shares of Nuvalent, Inc. for $124.00 per share in cash. This offer is made under an Agreement and Plan of Merger dated June 9, 2026. Nuvalent's Board of Directors has recommended that its stockholders accept the offer, which is set to expire on July 14, 2026. The acquisition is subject to customary closing conditions, including a minimum tender condition and regulatory approvals.
Key Highlights
- GSK's subsidiary, Harmony Row Acquisition Co., commenced a tender offer for Nuvalent.
- Offer to purchase all Class A and Class B shares of Nuvalent, Inc. (NASDAQ: NUVL).
- The offer price is $124.00 per share, net to the seller in cash.
- The tender offer is made pursuant to a merger agreement dated June 9, 2026.
- Nuvalent's Board of Directors recommends stockholders accept the offer.
- The offer and withdrawal rights will expire on July 14, 2026, at 11:59 p.m. ET.
- Conditions include a minimum tender of a majority of Class A Shares and HSR Act expiration.
Price Impact
More from GSK